NC
TBPH icon

nVerses Capital’s Theravance Biopharma TBPH Stock Holding History

nVerses Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
+14,772
New +$245K 0.39% 105

Other funds holding TBPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

nVerses Capital's TBPH Position: Q2 2026 in Review

nVerses Capital opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 14,772 shares worth $251K. The stake represents 0.39% of the portfolio and ranks #105 among its holdings.

120 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • nVerses Capital held 14,772 shares of Theravance Biopharma worth $251K as of Q2 2026.
  • Theravance Biopharma was a new nVerses Capital position in Q2 2026.
  • Theravance Biopharma made up 0.39% of nVerses Capital's portfolio in Q2 2026, its #105 holding.
  • 120 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.